256 related articles for article (PubMed ID: 11740344)
1. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
[TBL] [Abstract][Full Text] [Related]
3. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
4. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
[TBL] [Abstract][Full Text] [Related]
7. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
[TBL] [Abstract][Full Text] [Related]
9. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
[TBL] [Abstract][Full Text] [Related]
10. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
11. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
[TBL] [Abstract][Full Text] [Related]
12. Phenytoin intoxication induced by fluvoxamine.
Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
16. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
17. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
20. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
